They decreased the expression of CD44, reduced the phosphorylation or expression of EGFR, Met, Akt, and NF-κB, completely inhibited EGFR/MET-Akt/NF-κB signaling activated by HGF and EGF, and showed a higher inhibition effect on cancer cells when combined with anticancer drugs cytarabine, pyirubicin, vincristine, and methotrexate [48,49,50,51]. Here, NFKB1 is linked to cancer.